康泰医学(300869) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥111,844,411.72, representing a 12.77% increase compared to ¥99,175,164.46 in the same period last year[5]. - Net profit attributable to shareholders reached ¥16,435,767.78, a significant increase of 277.67% from ¥4,351,935.11 in the previous year[5]. - The basic earnings per share rose to ¥0.0409, up 278.70% from ¥0.0108 in the previous year[5]. - Total operating revenue for the current period reached ¥111,844,411.72, an increase of 12.7% compared to ¥99,175,164.46 in the previous period[17]. - Net profit for the current period was ¥16,435,767.78, a significant increase of 276.5% compared to ¥4,351,935.11 in the previous period[18]. - The company reported a total comprehensive income of ¥16,574,365.03, compared to ¥4,216,671.58 in the previous period, marking a substantial increase[19]. Cash Flow - The net cash flow from operating activities was ¥29,947,843.54, a remarkable increase of 5,580.54% compared to a negative cash flow of ¥546,439.44 in the same period last year[5]. - Operating cash flow generated was ¥29,947,843.54, a turnaround from a negative cash flow of ¥546,439.44 in the previous period[21]. - Net cash flow from investment activities was -19,016,952.58, compared to 280,116,061.20 in the previous period[22]. - Cash inflow from financing activities totaled 53,446,896.37, down from 143,160,301.37 year-over-year[22]. - Cash outflow for financing activities was 963,194.31, significantly lower than 142,278,214.92 in the previous period[22]. - The net increase in cash and cash equivalents was 63,074,699.29, compared to 282,350,673.49 previously[22]. - The ending balance of cash and cash equivalents was 747,382,470.77, slightly down from 749,573,920.22[22]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,787,405,167.13, reflecting a 2.27% increase from ¥2,725,517,187.03 at the end of the previous year[5]. - Total current assets increased to ¥2,144,746,579.76 from ¥1,921,219,260.88, representing a growth of approximately 11.7%[15]. - Total liabilities increased to ¥913,415,052.18, compared to ¥868,101,437.11 in the previous period, reflecting a growth of 5.2%[16]. - Non-current assets totaled ¥642,658,587.37, down from ¥804,297,926.15, indicating a decrease of approximately 20.1%[15]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 31,459[11]. - The largest shareholder, Hu Kun, holds 46.84% of shares, totaling 188,189,252 shares[11]. - The company's equity attributable to shareholders increased to ¥1,873,990,114.95, a 0.89% rise from ¥1,857,415,749.92 at the end of the previous year[5]. - Total equity attributable to shareholders reached ¥1,873,990,114.95, up from ¥1,857,415,749.92, indicating a growth of 0.9%[16]. Other Financial Metrics - The company reported a significant increase in prepayments, which rose by 54.9% to ¥9,570,191.80 due to increased procurement payments[9]. - The company experienced a 285.88% increase in taxes payable, amounting to ¥5,899,560.77, attributed to higher sales and profit levels[9]. - Research and development expenses were ¥22,572,126.74, down 16.8% from ¥27,140,047.87 in the previous period[18]. - Total operating costs decreased to ¥93,516,783.56, down 8.1% from ¥102,176,199.13 in the previous period[17]. - Trading financial assets rose significantly to ¥672,307,189.11 from ¥171,588,083.19, indicating a growth of approximately 292.5%[13]. - Short-term borrowings increased to ¥91,436,896.37 from ¥60,000,000.00, reflecting a rise of approximately 52.4%[15]. - Accounts receivable decreased slightly to ¥45,683,043.03 from ¥45,998,781.84[15]. - Inventory decreased to ¥265,882,645.56 from ¥272,322,956.49, showing a decline of approximately 2.4%[15]. - Non-recurring gains and losses totaled ¥2,666,103.66, primarily driven by government subsidies and fair value changes of financial assets[6]. Audit Status - The company has not yet audited its first-quarter report for 2025[23].